文献速递脑血管病

ANGEL-ASPECT试验:大梗死核心血管内治疗1年结局

Endovascular Therapy Versus Medical Management for Large Ischemic Infarct: 1-Year Outcomes of the ANGEL-ASPECT Trial.
PubMed 文献 · Stroke · 2025-08-25

ANGEL-ASPECT试验的1年预设分析显示,在前循环大血管闭塞且大梗死核心患者中,血管内治疗较药物治疗可改善1年改良Rankin量表分布(广义优势比1.25,95%CI 1.01-1.56;P=0.04),功能独立和独立行走比例更高,但1年死亡率无显著差异。

要点

  • 血管内治疗组1年mRS分布优于药物治疗组(广义优势比1.25,P=0.04)。
  • 血管内治疗组功能独立(mRS 0-2)比例30.4% vs 17.1%,独立行走(mRS 0-3)50.0% vs 35.6%。
  • 1年死亡率两组无显著差异(31.3% vs 26.5%,相对风险1.12,95%CI 0.82-1.53)。

核心结论

  • 对于发病24小时内前循环近端大血管闭塞所致大梗死核心卒中患者,血管内治疗较药物治疗可减少残疾,且1年获益持久。

研究设计与样本

  • ANGEL-ASPECT为3期随机、开放标签、盲法终点评估试验,纳入中国46家医院的前循环大血管闭塞且Alberta卒中项目早期CT评分3-5分或梗死核心体积70-100 mL的患者,1:1随机分配至血管内治疗或药物治疗。
  • 本分析为预设分析,主要结局为1年改良Rankin量表评分向更好结局的偏移,425/455例(93%)患者有1年主要结局数据(血管内治疗组214例,药物治疗组211例)。

主要发现

  • 1年改良Rankin量表分布向更好结局偏移的广义优势比为1.25(95%CI 1.01-1.56;P=0.04),血管内治疗组优于药物治疗组。
  • 功能独立(mRS 0-2)比例血管内治疗组30.4%(65/214) vs 药物治疗组17.1%(36/211),相对风险1.87(95%CI 1.27-2.75)。
  • 独立行走(mRS 0-3)比例血管内治疗组50.0%(107/214) vs 药物治疗组35.6%(75/211),相对风险1.46(95%CI 1.15-1.85)。
  • 1年死亡率血管内治疗组31.3%(67/214) vs 药物治疗组26.5%(56/211),相对风险1.12(95%CI 0.82-1.53)。
  • 血管内治疗组功能独立比例从90天至1年无变化(29.4% vs 30.4%),药物治疗组从10.9%增至17.1%,治疗效应幅度从90天的18.5%缩小至1年的13.3%。

关键数值与推荐

  • 主要结局为1年改良Rankin量表评分(范围0-6,评分越高残疾越重)向更好结局的偏移。
  • 次要结局包括功能独立(mRS 0-2)、独立行走(mRS 0-3)和死亡率。

临床怎么用

  • 对于符合ANGEL-ASPECT入组标准的大梗死核心卒中患者,血管内治疗可作为改善长期功能结局的选择。
  • 需权衡1年死亡率无显著差异及药物治疗组功能独立比例随时间增益导致治疗效应缩小的因素。

局限性

  • 1年主要结局数据仅覆盖93%(425/455)的患者,采用完整病例分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several trials have shown the benefit and safety of endovascular therapy (EVT) compared with medical management (MM) of patients with a large ischemic core in the 90-day follow-up. However, the 1-year outcome comparison between EVT and MM in Asian patients with a large ischemic core has not been investigated. Our aim was to evaluate the 1-year outcomes of patients in the ANGEL-ASPECT trial (Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core). METHODS: In this phase 3, randomized, open-label, blinded end point assessment trial, patients with anterior circulation large vessel occlusion and an Alberta Stroke Program Early CT Score of 3 to 5 or an infarct core volume of 70 to 100 mL were enrolled across 46 hospitals in China. Patients were randomly assigned 1:1 to EVT or MM. The 90-day outcomes were previously reported. We report a prespecified analysis of the ANGEL-ASPECT trial, with 1-year functional outcome as the primary outcome in this study. The primary outcome was the shift of the modified Rankin Scale (mRS) score (range, 0-6, with a higher score reflecting greater disability) to better outcomes at 1-year. The secondary outcomes included functional independence (mRS score, 0-2), independent ambulation (mRS score, 0-3), and mortality. This trial is registered with https://www.clinicaltrials.gov (Unique identifier: NCT04551664). RESULTS: One-year data were available for 425 of 455 (93%) patients for the primary outcome, with 214 patients in the EVT group and 211 in the MM group in the complete case analysis. The mean age was 66 years, and 38.1% were female. There was a greater likelihood of shift toward improved 1-year mRS distribution in the EVT compared with the MM group (generalized odds ratio, 1.25 [95% CI, 1.01-1.56]; P=0.04). Functional independence and independent ambulation were higher in the EVT compared with MM groups (mRS score, 0-2: 30.4% [65/214] versus 17.1% [36/211]; relative risk, 1.87 [95% CI, 1.27-2.75]; mRS score, 0-3: 50.0% [107/214] versus 35.6% [75/211]; relative risk, 1.46 [95% CI, 1.15-1.85], respectively). The 1-year mortality rate was 31.3% (67/214) in the EVT group and 26.5% (56/211) in the MM group (relative risk, 1.12 [95% CI, 0.82-1.53]). In addition, no change was found in the rate of functional independence between 90 days and 1 year in the EVT group (29.4% [69/214] versus 30.4% [65/214], respectively); however, a gain in functional independence was observed in the MM group from 90 days to 1 year (10.9% [26/211] versus 17.1% [36/211]), narrowing the magnitude of EVT treatment effect from 18.5% at 90 days to 13.3% at 1 year. CONCLUSIONS: In patients with large ischemic stroke from a proximal arterial occlusion presenting within 24 hours of onset, EVT reduced disability with durable 1-year benefit compared with MM. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04551664.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Huo X, Sun D, Nguyen TN, et al. Endovascular Therapy Versus Medical Management for Large Ischemic Infarct: 1-Year Outcomes of the ANGEL-ASPECT Trial. Stroke. 2025. PMID: 40854041. doi:10.1161/STROKEAHA.124.050086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。